CA2371912C - Agents a stabilisation proteinique actifs pharmacologiquement; procedes de fabrication et methodes d'utilisation - Google Patents

Agents a stabilisation proteinique actifs pharmacologiquement; procedes de fabrication et methodes d'utilisation Download PDF

Info

Publication number
CA2371912C
CA2371912C CA2371912A CA2371912A CA2371912C CA 2371912 C CA2371912 C CA 2371912C CA 2371912 A CA2371912 A CA 2371912A CA 2371912 A CA2371912 A CA 2371912A CA 2371912 C CA2371912 C CA 2371912C
Authority
CA
Canada
Prior art keywords
paclitaxel
pharmacologically active
patients
abi
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2371912A
Other languages
English (en)
Other versions
CA2371912A1 (fr
Inventor
Neil P. Desai
Chunlin Tao
Andrew Yang
Leslie Louie
Zhiwen Yao
Patrick Soon-Shiong
Shlomo Magdassi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abraxis Bioscience LLC
Original Assignee
Abraxis Bioscience LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/316,642 external-priority patent/US6749868B1/en
Application filed by Abraxis Bioscience LLC filed Critical Abraxis Bioscience LLC
Priority to CA2684454A priority Critical patent/CA2684454A1/fr
Publication of CA2371912A1 publication Critical patent/CA2371912A1/fr
Application granted granted Critical
Publication of CA2371912C publication Critical patent/CA2371912C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des compositions et des procédés convenant pour l'administration in vivo d'agents pharmacologiquement actifs essentiellement insolubles dans l'eau (tels que le médicament anticancéreux paclitaxel) dans lesquels un agent actif au plan pharmacologique est administré sous forme de particules en suspension enrobées d'une protéine (laquelle agit comme agent stabilisateur). En particulier, la protéine et l'agent pharmacologiquement actif présents dans un support dispersant biocompatible sont soumis à un cisaillement élevé en l'absence de tout tensioactif classique et en l'absence de matériau noyau polymère pour les particules. Le procédé selon l'invention permet d'obtenir des particules d'un diamètre inférieur au micron. L'utilisation d'une composition spécifique dans des conditions de préparation précises (adjonction d'un solvant polaire à la phase organique), et le choix raisonné de la phase organique appropriée et de la fraction de phase permet la production reproductible de nanoparticules exceptionnellement petites d'un diamètre inférieure à 200 nm qui peuvent être stérilisées par filtration. Le système de particules obtenu dans le cadre de l'invention peut être transformé en une poudre sèche redispersible comprenant des nanoparticules d'un médicament enrobé d'une protéine, insoluble dans l'eau, et d'une protéine libre à laquelle des molécules de l'agent pharmacologique sont liées. On obtient ainsi un système d'administration unique en son genre dans lequel un agent actif au plan pharmacologique est facilement biodisponible (sous forme de molécules liées à la protéine), et où une partie de l'agent est présente dans les particules sans aucune matrice polymère.
CA2371912A 1999-05-21 2000-05-19 Agents a stabilisation proteinique actifs pharmacologiquement; procedes de fabrication et methodes d'utilisation Expired - Lifetime CA2371912C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2684454A CA2684454A1 (fr) 1999-05-21 2000-05-19 Agents a stabilisation proteinique actifs pharmacologiquement; procedes de fabrication et methodes d'utilisation

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/316,642 1999-05-21
US09/316,642 US6749868B1 (en) 1993-02-22 1999-05-21 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
PCT/US2000/013954 WO2000071079A2 (fr) 1999-05-21 2000-05-19 Agents a stabilisation proteinique actifs pharmacologiquement; procedes de fabrication et methodes d'utilisation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2684454A Division CA2684454A1 (fr) 1999-05-21 2000-05-19 Agents a stabilisation proteinique actifs pharmacologiquement; procedes de fabrication et methodes d'utilisation

Publications (2)

Publication Number Publication Date
CA2371912A1 CA2371912A1 (fr) 2000-11-30
CA2371912C true CA2371912C (fr) 2010-02-16

Family

ID=23229970

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2684454A Abandoned CA2684454A1 (fr) 1999-05-21 2000-05-19 Agents a stabilisation proteinique actifs pharmacologiquement; procedes de fabrication et methodes d'utilisation
CA2371912A Expired - Lifetime CA2371912C (fr) 1999-05-21 2000-05-19 Agents a stabilisation proteinique actifs pharmacologiquement; procedes de fabrication et methodes d'utilisation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2684454A Abandoned CA2684454A1 (fr) 1999-05-21 2000-05-19 Agents a stabilisation proteinique actifs pharmacologiquement; procedes de fabrication et methodes d'utilisation

Country Status (5)

Country Link
EP (1) EP1178786A4 (fr)
AU (3) AU784416B2 (fr)
CA (2) CA2684454A1 (fr)
HK (1) HK1045646A1 (fr)
WO (1) WO2000071079A2 (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
JP2003512443A (ja) * 1999-10-27 2003-04-02 ベーカー ノートン ファーマシューティカルズ インコーポレイテッド タキサンをヒト患者に経口投与するための方法及び組成物
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US7037528B2 (en) 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
BR0212833A (pt) 2001-09-26 2004-10-13 Baxter Int Preparação de nanopartìculas de tamanho submìcron através de dispersão e de remoção de solvente ou de fase lìquida
CN1592607A (zh) 2001-10-15 2005-03-09 克里蒂泰克公司 水溶性差药物的组合物、其给药方法和治疗方法
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
ITMI20020680A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
NZ518997A (en) * 2002-05-16 2004-12-24 Interag Injection formulation for parenteral administration of biodegradable implant for sustained release of active agent
SI21222A (sl) * 2002-05-28 2003-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek za pripravo nanodelcev
GB0216700D0 (en) 2002-07-18 2002-08-28 Astrazeneca Ab Process
CA2509365C (fr) 2002-12-09 2012-08-07 American Bioscience, Inc. Compositions et methodes d'administration d'agents pharmacologiques
GB0302673D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
IL160095A0 (en) * 2004-01-28 2004-06-20 Yissum Res Dev Co Formulations for poorly soluble drugs
CN101102740A (zh) * 2005-01-07 2008-01-09 卫材R&D管理有限公司 药用组合物以及其制备方法
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
KR20070114753A (ko) 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
WO2006138202A2 (fr) * 2005-06-14 2006-12-28 Baxter International Inc. Preparations pharmaceutiques permettant de reduire les interactions entre medicaments
LT3311805T (lt) * 2005-08-31 2020-04-27 Abraxis Bioscience, Llc Kompozicijos, apimančios silpnai vandenyje tirpius farmacinius agentus ir priešmikrobinius agentus
BRPI0617663A2 (pt) * 2005-10-21 2011-08-02 Panacea Biotec Ltd composições aperfeiçoadas para terapia de cáncer
US8980323B2 (en) 2006-08-29 2015-03-17 Fujifilm Corporation Hydrophilic matrix containing poorly water-soluble compound and method for producing the same
EP3470071A1 (fr) 2006-12-14 2019-04-17 Abraxis BioScience, LLC Thérapie contre le cancer du sein fondée sur le statut des récepteurs hormonaux, dans laquelle sont utilisées des nanoparticules comprenant du taxane
EP2131821B1 (fr) 2007-03-07 2018-05-09 Abraxis BioScience, LLC Nanoparticule comprenant de la rapamycine et de l'albumine utilisée comme agent anticancéreux
JP5579057B2 (ja) 2007-06-01 2014-08-27 アブラクシス バイオサイエンス， エルエルシー 再発性癌の処置のための方法および組成物
FR2924024B1 (fr) * 2007-11-27 2012-08-17 Centre Nat Rech Scient Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse
KR20100048751A (ko) * 2008-10-31 2010-05-11 주식회사 동성바이오레인 스프레이 가능한 캡슐화된 기능성 미립자 조성물과 그 제조방법
CA2750421C (fr) * 2008-11-27 2016-10-18 B.R.A.I.N. Biotechnology Research And Information Network Ag Proteines tensioactives en tant qu'excipients dans des formulations pharmaceutiques solides
KR101722961B1 (ko) 2009-02-11 2017-04-04 알부메딕스 에이/에스 알부민 변이체 및 접합체
PT2419732T (pt) 2009-04-15 2019-12-24 Abraxis Bioscience Llc Composições e métodos de nanopartículas isentas de priões
EP2493921B1 (fr) 2009-10-30 2018-09-26 Albumedix Ltd Variants d'albumine
NZ602382A (en) 2010-03-26 2014-11-28 Abraxis Bioscience Llc Methods of treatment of hepatocellular carcinoma
EP3141245A1 (fr) 2010-03-29 2017-03-15 Abraxis BioScience, LLC Méthodes de traitement du cancer
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
MX347225B (es) 2010-06-04 2017-04-19 Abraxis Bioscience Llc * Metodos de tratamiento contra el cancer pancreatico.
EP3560486A1 (fr) 2011-12-14 2019-10-30 Abraxis BioScience, LLC Utilisation d'excipients polymères pour la lyophilisation ou la congélation de particules
DK2825556T3 (en) 2012-03-16 2018-04-16 Albumedix As albumin Variants
MX2015005363A (es) 2012-11-08 2015-11-06 Novozymes Biopharma Dk As Variantes de albumina.
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
PT106738B (pt) * 2013-01-09 2015-06-08 Hovione Farmaciencia Sa Método para o controlo do fenómeno de degradação difusional de ostwald (ostwald ripening) no processamento de partículas de um ingrediente farmacêutico
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
US20160033523A1 (en) 2013-02-16 2016-02-04 Novozymes Biopharma Dk A/S Pharmacokinetic animal model
EP3698784A1 (fr) 2013-03-12 2020-08-26 Abraxis BioScience, LLC Procédés de traitement du cancer du poumon
RU2015143490A (ru) 2013-03-14 2017-04-26 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения рака мочевого пузыря
CN104548116A (zh) * 2013-10-11 2015-04-29 程树海 一种稳定的蛋白质载药微粒系统制备方法
WO2015018380A2 (fr) 2014-07-03 2015-02-12 Cspc Zhongqi Pharmaceutical Technology(Shijiazhuang)Co., Ltd. Nanoparticules thérapeutiques et leurs procédés de préparation
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
ES3009356T3 (en) 2015-06-29 2025-03-26 Abraxis Bioscience Llc Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors
JP7007261B2 (ja) 2015-08-20 2022-01-24 アルブミディクス リミティド アルブミン変異体及びコンジュゲート
EP3535585A1 (fr) 2016-11-04 2019-09-11 Aarhus Universitet Identification et traitement de tumeurs caractérisées par une surexpression du récepteur fc néonatal
DE102016125666A1 (de) 2016-12-23 2018-06-28 Michael Denck HSA-Galenik
EP3615011A4 (fr) * 2017-04-24 2021-01-06 ZY Therapeutics Inc. Composition pharmaceutique pour l'administration in vivo, procédé de préparation d'un principe pharmacologiquement actif sensiblement insoluble dans l'eau
IL277402B1 (en) 2018-03-20 2026-04-01 Abraxis Bioscience Llc Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin
BR112022007710A2 (pt) 2019-10-28 2022-07-12 Abraxis Bioscience Llc Composições farmacêuticas de albumina e rapamicina
CN114786654A (zh) * 2019-12-11 2022-07-22 密执安大学评议会 用于全身递送Bcl-2和Bcl-xL拮抗剂的组合物和方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671954A (en) * 1983-12-13 1987-06-09 University Of Florida Microspheres for incorporation of therapeutic substances and methods of preparation thereof
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
PT1023050E (pt) * 1997-06-27 2013-12-04 Abraxis Bioscience Llc Novas formulações de agentes farmacológicos, métodos para a sua preparação e métodos para a sua utilização

Also Published As

Publication number Publication date
CA2371912A1 (fr) 2000-11-30
EP1178786A1 (fr) 2002-02-13
WO2000071079A3 (fr) 2008-03-27
AU2006202836A1 (en) 2006-07-27
HK1045646A1 (zh) 2002-12-06
EP1178786A4 (fr) 2006-03-01
CA2684454A1 (fr) 2000-11-18
AU784416B2 (en) 2006-03-30
AU2009217409A1 (en) 2009-10-08
WO2000071079A2 (fr) 2000-11-30
AU2006202836B2 (en) 2009-10-08
AU5035900A (en) 2000-12-12

Similar Documents

Publication Publication Date Title
CA2371912C (fr) Agents a stabilisation proteinique actifs pharmacologiquement; procedes de fabrication et methodes d'utilisation
US6749868B1 (en) Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
CA2267498C (fr) Agents pharmaceutiquement actifs stabilises par proteine, procedes de preparation et procedes d'utilisation
US8137684B2 (en) Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20150104521A1 (en) Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20070117863A1 (en) Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20080161382A1 (en) Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
EP2272504A2 (fr) Nouvelles formulations d'agents pharmacologiques, leurs procédés de préparation et d'utilisation
HK1119974A (en) Methods for the preparation of protein stabilized pharmacologically active agents
HK1119974B (en) Methods for the preparation of protein stabilized pharmacologically active agents
HK1024866B (en) Protein stabilized pharmacologically active agents and their use
HK1154511A (en) Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
HK1152882A (en) Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20200519